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SUMMARY 31 
Objective: Previous studies suggest that androgens have a sexually dimorphic impact on metabolic 32 
dysfunction. However, the sex-specific link between circulating androgens and risk of type 2 diabetes 33 
mellitus (T2DM) has not been examined in a large scale, longitudinal cohort, a task we undertook in this 34 
study.  35 
Design: A retrospective cohort study in a UK primary care database.  36 
Patients: We included men and women with available serum testosterone and sex hormone-binding 37 
globulin (SHBG) results.  38 
Measurements: We categorized serum concentrations according to clinically relevant cut-off points and 39 
calculated crude and adjusted T2DM Incidence Rate Ratios (IRRs and aIRRs).  40 
Results: Serum testosterone concentrations were available in 70,541 men and 81,889 women; serum 41 
SHBG was available in 15,907 men and 42,034 women. In comparison to a reference cohort with serum 42 
testosterone ≥20nmol/l, men with lower serum testosterone had a significantly increased risk of T2DM, 43 
with the highest risk in those with serum testosterone <7nmol/l (aIRR 2.71, 95% CI 2.34-3.14, p<0.001). 44 
In women, the risk of T2DM started to increase significantly when serum testosterone concentrations 45 
exceeded 1.5nmol/l, with the highest risk in women with serum testosterone ≥3.5nmol/l (aIRR 1.98, 95% 46 
CI 1.55-2.52, p<0.001). These observations were verified in a continuous rather than categorized analysis. 47 
The risk of T2DM increased in men and women with serum SHBG <40nmol/L and <50nmol/L, 48 
respectively.  49 
Conclusions/Interpretation: In this longitudinal study, we found sexually dimorphic associations 50 
between serum testosterone and risk of incident T2DM. Androgen deficiency and excess should be 51 
considered important risk factors for diabetes in men and women, respectively.  52 
Key words: Testosterone, androgens, hypogonadism, sex hormone-binding globulin, diabetes, metabolic 53 
diseases, population health  54 
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INTRODUCTION 55 
Sex differences are critical in the epidemiology and pathophysiology of metabolic disease, with 56 
an increased incidence of type 2 diabetes mellitus (T2DM) and cardiovascular disease in men 1. Sex 57 
hormones such as androgens may mediate these differences, but the association between androgens and 58 
metabolic dysfunction is complex and sex-specific 2. Androgen excess has recently been identified as an 59 
independent risk factor for non-alcoholic fatty liver disease (NAFLD) in women 3, and promotes lipid 60 
accumulation in female adipose tissue as well as systemic lipotoxicity 4. Female-to-male gender 61 
reassignment patients undergoing androgen therapy develop dyslipidemia and abnormal body 62 
composition 5,6. Mirroring this, the adverse metabolic phenotype of male androgen deficiency bears a 63 
striking similarity to that of female androgen excess; lower testosterone levels in men are associated with 64 
impaired glucose homeostasis, hepatic steatosis and coronary artery disease 7-9. A number of meta-65 
analyses support a sex-specific relationship between androgens and the risk of metabolic dysfunction, and 66 
suggest that low circulating sex hormone-binding globulin (SHBG) concentrations may be metabolically 67 
harmful in both sexes 9,10.  68 
Delineating an independent role for androgens in the pathogenesis of T2DM is confounded by 69 
changes in body composition, body mass index and lean mass observed in disorders of androgen excess 70 
and deficiency 11. Against the background of a global epidemic of T2DM 12, there is an urgent health need 71 
to understand the sexually dimorphic role played by androgens in the pathogenesis of hyperglycemia. The 72 
shared constellation of risk factors observed in women with androgen excess and men with androgen 73 
deficiency suggests that circulating androgen concentrations common to both disorders may be 74 
metabolically disadvantageous 2. To our knowledge, however, no large longitudinal studies have 75 
specifically examined the association between circulating androgen exposure per se and risk of T2DM in 76 
a sex-specific context.   77 
The aim of this study was to investigate the independent sex-specific association between serum 78 
testosterone concentrations and the risk of hyperglycaemia in men and women by undertaking a 79 
retrospective cohort study in a large and diverse UK population base.   80 
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MATERIALS AND METHODS 81 
Database 82 
A large primary care database in the UK with contribution from over 700 general practices (14 83 
million patients) was utilized for this study. Data from practices that use VISION Electronic Medical 84 
Record (EMR) are gathered, anonymized and released for research purpose 13. The resulting database, 85 
The Health Improvement Network (THIN) database holds data on demographic characteristics, clinical 86 
diagnosis, physical measurement, laboratory results and prescriptions. The THIN database is broadly 87 
representative of the UK population structure 14 and has been utilized for numerous epidemiological 88 
studies, including studies on T2DM 15,16 and sex hormones 3,17,18. 89 
Testosterone and Sex Hormone Binding Globulin (SHBG) measurements  90 
Men or women over the age of 16 who had a measurement of the serum concentration of 91 
testosterone or SHBG between 1st of Jan 2000 and 15th of May 2016 were eligible to take part in the 92 
study. Common clinical indications for these measurements include suspected polycystic ovary syndrome 93 
(PCOS) in women, infertility investigations in both sexes and erectile dysfunction in men 19,20 . Where 94 
multiple measurements were available in one individual, the first measurement was utilized. Patients with 95 
the outcome of interest (T2DM) preceding the index date were excluded from the study. 96 
Exposure categories 97 
To explore non-linear relationships, establish gradient increase and assess risk within the normal 98 
range, measurements were categorized by applying clinically relevant cut-off points for serum 99 
concentrations (nmol/L)3. For women, testosterone was grouped as <1.0nmol/L (reference group), 1.0-100 
1.49, 1.5- 1.99, 2.0-2.49, 2.5-2.99, 3.0-3.49 and >3.5 nmol/L. For men, the groups were as follows: <7, 7-101 
9.9, 10.0-14.9, 15-19.9, >20.0nmol/L (reference group) nmol/L. For both sexes, SHBG was categorized 102 
as >60.0nmol/L (reference group), 50.0-59.9, 40.0-49.9, 30.0-39.9, 20.0-29.9 and < 20 nmol/L. Exposures 103 
were also treated as continuous variables and risk of T2DM assessed.  104 
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Follow-up period 105 
The date of measurement of testosterone or SHBG served as the index date. Each participant was 106 
followed-up from the index date until the exit date. Exit date was defined as the earliest of the following 107 
dates: outcome (diagnosis of T2DM), study end, death or the date they left the general practice or the 108 
general practice stopped contributing to the database.  109 
 Outcome and covariates 110 
A clinical diagnosis of T2DM by the general practitioner was the outcome of interest. In the UK, 111 
the Quality Outcome Framework (QOF) in general practices ensures high quality data on important 112 
comorbidities such as cardiovascular disease, hypertension and T2DM 21 . Within the database, diagnostic 113 
codes for T2DM were identified based on Read codes, a hierarchical coding system to record signs, 114 
symptoms, procedures and diagnosis in primary care 3. Covariates that are independent predictors of 115 
T2DM other than the exposure of interest were selected on the basis of biological plausibility and 116 
previous literature 22. These included age, body mass index (BMI), Townsend deprivation score and 117 
smoking status. 118 
Statistical analysis 119 
Baseline data of each category in the serum testosterone and SHBG cohorts was reported 120 
separately for men and women as mean (standard deviation) or median (interquartile range [IQR]) as 121 
appropriate for continuous variables and as proportions for categorical variables. Crude Incidence Rate 122 
Ratio (IRR) and adjusted Incidence Rate Ratio (aIRR) were calculated by applying Poisson regression 123 
offsetting for the person years of follow-up. Covariates adjusted for in the model were age, BMI, 124 
Townsend quintiles and smoking status. In women, an additional model included polycystic ovary 125 
syndrome (PCOS) as a covariate to explore if the risk of T2DM in women was independent of a diagnosis 126 
of PCOS. In an additional sensitivity analysis, when adjusting for PCOS. we accepted the presence of 127 
hirsutism and anovulation as indicative of PCOS given that the diagnosis is underreported in primary 128 
care.  129 
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Where missing data existed (BMI, Townsend or smoking), we created a separate category so that 130 
all available data is utilized in the analysis. BMI was categorized as per WHO recommendation into 131 
<25.0kg/m2, 25-29.0kg/m2 and >30kg/m2. All analyses were performed in STATA 14.0. 132 
Subgroup analysis 133 
In women, we performed stratified analysis by age (<50 years and 50 years and above) to explore 134 
if the association was similar before and after the average age of menopause. A similar age-stratified 135 
analysis was also carried out in men. In addition to this, in those patients with simultaneous 136 
measurements of testosterone and SHBG, a free androgen index (FAI) was calculated [(Tx100)/SHBG], 137 
and risk of T2DM calculated to control for the confounding effect of low SHBG levels.  138 
Ethical Approval 139 
This study used routinely collected, anonymised primary care data. Patients were not involved in 140 
the study, and therefore no consent was required. Research using THIN data was approved by the NHS 141 
South-East Multicentre Research Ethics Committee in 2003, with the condition that studies undergo 142 
independent scientific review 23. Approval for this analysis was obtained from the Scientific Review 143 
Committee for the use of THIN data in January 2018 (SRC reference number 17THIN106). 144 
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RESULTS 145 
Characteristics of the cohorts with serum testosterone and SHBG measurements 146 
A total of 152,430 participants in the cohort with available serum testosterone measurement 147 
results (testosterone cohort; 70,541 men and 81,889 women) and a total of 57,942 participants (15,907 148 
men and 42,035 women) in the SHBG cohort, both derived from the THIN database, met the inclusion 149 
criteria and were included in the current study. Median follow-up in the testosterone cohort was 3.3 150 
years (IQR:1.5-6.1) in men and 3.2 (IQR:1.3-6.2) years in women. In the SHBG cohort, median follow-151 
up was 2.8 (1.3-4.9) years in men and 2.8 (1.2-5.4) in women. The mean age for men was 51.6 (SD 152 
14.8) years in the testosterone cohort and 51.7 (SD 16.0) years in the SHBG cohort. For women, mean 153 
age was 33.2 (SD 10.9) years in the testosterone cohort and 32.1 (SD 10.6) years in in the SHBG 154 
cohort. In total, 40,464 (57.4%) men in the testosterone cohort and 9,795 (61.6%) men in the SHBG 155 
cohort were overweight or obese (BMI ≥25kg/m2). Among women, 36,640 (44.7 %) were obese or 156 
overweight in the testosterone cohort and 19,270 (45.8%) in the SHBG cohort. Approximately 21% of 157 
men and 22% of women were smokers across both testosterone and SHBG cohorts (Table 1). A diagnosis 158 
of PCOS was only documented in 6.3% (N=5,136) and 7.9% (N=3,303) of the female testosterone and 159 
SHBG cohorts, respectively. However, clinical features suggestive of PCOS, anovulation and clinical 160 
evidence of hirsutism, were documented in 25.8% and 11.2% of the female testosterone cohort, 161 
respectively, and in 26.9% and 12.1% of the female SHBG cohort, respectively.  162 
Biochemical evidence of male androgen deficiency (serum testosterone <7nmol/L) was observed 163 
in 5,862 men (8.3%). Biochemical evidence of female androgen excess (serum testosterone >2nmol/L) 164 
was observed in 20,565 women (25.1%); of those, 2,481 women (3.0%) had severe androgen excess 165 
(serum testosterone 3.5 nmol/L). Serum SHBG concentrations <20nmol/L were observed in 2,517 166 
(15.8%) men and 3,733 (8.9 %) women (Suppl. Tables 1-4).   167 
Association between sex hormones and T2DM risk in men  168 
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Among 70,541 men with serum testosterone measurements, 3,156 developed T2DM during the 169 
follow-up period. As expected, increasing age, overweight/obesity, smoking and higher social deprivation 170 
conferred an increased risk for T2DM (Suppl. Tables 5 and 6). 171 
After adjusting for age, BMI, Townsend index and smoking status, aIRR for T2DM in men 172 
increased with decreasing categories of serum testosterone concentrations, most notably a 271% higher 173 
risk of developing T2DM in those with testosterone levels <7nmol/L, compared to the reference category 174 
of 20nmol/L (aIRR 2.71, 95% CI 2.34-3.14, p<0.001, Table 2). However, the risk of T2DM increased 175 
even within the normal male testosterone range (15-19.99 nmol/L, aIRR 1.29, 95% CI 1.13-1.47, 176 
p<0.001; 10-14.99 nmol/L, aIRR 1.90, 95% CI 1.68-2.15, p<0.001, Table 2 & Figure 1A+B).   177 
In the SHBG cohort, among 15,907 men studied, there were 708 cases of incident T2DM during 178 
the follow-up period. After adjusting for age, BMI, Townsend index and smoking status, the risk of 179 
T2DM increased in men with SHBG levels <40nmol/L; aIRR of incident T2DM increased across 180 
categories of decreasing SHBG concentrations as compared to the reference category (≥60nmol/L) and 181 
the risk was more than 5-fold higher in the group with SHBG <20nmol/L (aIRR 5.74, 95% CI 3.72-8.87, 182 
Table 2 & Figure 1C+D).  183 
Association between sex hormones and T2D risk in women  184 
Among 81,889 women with serum testosterone measurements, 1,282 developed T2DM during 185 
the follow-up period. After adjusting for age, BMI, Townsend index and smoking status, T2DM aIRR 186 
tended to be higher with increasing serum testosterone levels. The risk increased significantly for serum 187 
testosterone levels >1.5 nmol/L, as compared to reference category (<1nmol/L), and continued to increase 188 
across each category of serum testosterone concentrations thereafter, with a two-fold increase in risk 189 
observed in women with serum testosterone ≥3.5 nmol/L (aIRR 1.98, 95% CI 1.55-2.52, p<0.001, Table 190 
2 & Figure 2A+B). Further adjustment for a diagnosis of PCOS or clinical features of suspected PCOS 191 
(hirsutism or anovulation) did not substantially change results (aIRR in subgroup of women with 192 
O’Reilly MW et al. 
  10
testosterone levels >3.5 nmol/L = 1.89, 95% CI 1.48-2.42, p<0.001 and 1.76, 95% CI 1.38-2.25, p<0.001 193 
respectively, Suppl. Table 7). 194 
 In the SHBG cohort, among 42,034 women studied, there were 597 cases of incident T2DM 195 
during the follow-up period. The risk of incident T2DM increased with each category of decreasing 196 
SHBG concentration. Women with serum SHBG concentrations <20nmol/L had a 9-fold higher risk of 197 
developing T2DM compared to the reference category of ≥60nmol/L (aIRR 9.23, 95% CI 6.61-12.88, 198 
p<0.001), after adjustment for age, BMI, Townsend index and smoking status (Table 2 & Figure 2C+D). 199 
Additional adjustment for a diagnosis of PCOS and clinical features of suspected PCOS did not alter the 200 
risk of T2DM (aIRR 9.13, 95% CI 6.53-12.75, p<0.001 and aIRR 8.88, 95% CI 6.36-12.42, p<0.001 201 
respectively, Suppl. Table 8).  202 
Analysis of sex hormones as a continuous variable  203 
In men, for every nmol/L decrease in testosterone, the risk of T2DM increased by 5% (aIRR 1.05, 204 
95% CI 1.04-1.06, p<0.001). In women, for every nmol/L increase in testosterone, the risk of T2DM 205 
increased by 10% (aIRR 1.10, 95% CI 1.06-1.14, p<0.001). In the analysis of SHBG, for every nmol/L 206 
decrease in SHBG the risk of T2DM increased by 3% in both men and women (aIRR 1.03, 95% CI 1.03-207 
1.04, p<0.001, in both sexes). 208 
Free androgen index and risk of T2DM 209 
Only 40% women (n=34,578) and 16% of men (n=12,178) had undergone a simultaneous 210 
measurement of serum SHBG and testosterone. Using these to calculate the free androgen index (FAI), 211 
we found that FAI was positively associated with risk of T2DM in women (aIRR 1.03, 95% CI 1.02-1.04, 212 
p<0.001), but not in men (aIRR 1.00, 95% CI 0.997-1.004, p=0.789). 213 
Subgroup analyses  214 
Subgroup analysis stratified by age (<50 and 50 years) did not alter the observed associations. In 215 
both age groups, a gradient increase in risk of T2DM was observed with increasing testosterone 216 
concentrations in women and decreasing testosterone concentrations in men (Suppl. Fig 1 and Suppl. 217 
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Tables 9-12). Increased aIRRs for T2DM were noted with lower concentrations of SHBG in both age 218 
groups in men and women (Suppl. Fig 2 and Suppl. Tables 13-16).  219 
DISCUSSION 220 
In this large retrospective cohort study, we have demonstrated that androgens confer an 221 
independent sex-specific effect on the risk of incident T2DM. To our knowledge, this is the largest study, 222 
and the first longitudinal analysis, to address the impact of serum testosterone on risk of development of 223 
T2DM in both men and women. In the female cohort, aIRRs for T2DM increased significantly once 224 
serum testosterone concentrations increased above 1.5nmo/L; even those with circulating testosterone 225 
levels between 1.5 and 1.99nmol/L, conventionally considered within the normal physiological range for 226 
women, already had a 23% increased risk of T2DM compared to the reference group. Perhaps even more 227 
surprisingly, once male serum testosterone concentrations dropped below 20nmol/L, the risk of T2DM 228 
began to increase; men with circulating concentrations between 15 and 19.99nmol/L, i.e. within the 229 
normal physiological male range, had a 28% increased risk of T2DM over the study period. Reduced 230 
SHBG concentrations in both sexes, but particularly in women, also potently increased the risk of T2DM. 231 
This finding is in agreement with observations from some previous studies, which demonstrated a 232 
stronger inverse association between SHBG levels and risk of T2DM in women compared to men 10,24. 233 
This inverse relationship with T2DM appears to be particularly strong in postmenopausal women 25. A 234 
2011 meta-analysis, however, found that higher SHBG levels were equally associated with a reduced risk 235 
of metabolic syndrome in both sexes 26.  236 
A systematic review and meta-analysis, which included a total of 3825 men and 4795 women in 237 
36 cross-sectional studies, as well as 368 cases from 7 prospective study populations, previously 238 
demonstrated that increased serum testosterone was associated with a 60% higher risk of T2DM in 239 
women; higher testosterone levels in men reduced the risk of T2DM by 42% 10. Goodman-Gruen et al 240 
also observed sex differences in the association between serum androgens and glucose tolerance status in 241 
an older community cohort of 775 men and 633 women above the age of 55 27. Men with impaired fasting 242 
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glucose, impaired glucose tolerance and T2DM had significantly lower levels of serum testosterone, 243 
while women with T2DM had significantly higher levels of bioavailable testosterone, independent of total 244 
body fat, fat distribution, physical activity and smoking.  However, our study is the only longitudinal 245 
retrospective analysis to comprehensively evaluate these associations.  246 
A number of key insights into the role of androgen excess in the development of metabolic 247 
dysfunction is provided by studies in women with polycystic ovary syndrome (PCOS), a disorder 248 
affecting up to 10% of the female population and primarily defined by the presence of hyperandrogenism 249 
and ovulatory dysfunction 28. We have recently demonstrated that lean women with PCOS have an almost 250 
two-fold increased risk of NAFLD, a hepatic manifestation of metabolic dysfunction, and that androgen 251 
excess is an independent mediator of this increased risk 3. Androgen-mediated adipose tissue lipotoxicity 252 
may contribute to this increase in NAFLD risk 4,29. PCOS women are at significantly increased risk of 253 
impaired glucose tolerance and T2DM at a young age, irrespective of body weight 30. A recent large 254 
Danish population register study concluded that the risk of T2DM was four-fold higher for women with 255 
PCOS, and diagnosed 4 years earlier, compared to women in the background population 31.  256 
Male androgen deficiency occurs as a consequence of primary testicular pathology, 257 
hypothalamic-pituitary disorders, obesity or as part of the ageing process in older men 32,33. Additionally, 258 
iatrogenic hypogonadism due to androgen deprivation therapy is observed in men with prostate cancer 34. 259 
Whilst the relationship between obesity and hypogonadism in men is complex and bidirectional 35, data 260 
from male cohorts treated with short term androgen deprivation therapy show that hypogonadism directly 261 
induces metabolically deleterious changes in body composition, with increases in weight and in 262 
percentage fat body mass 36. However, studies of androgen deprivation therapy, which result in significant 263 
hypogonadism, are not an ideal model to compare to the relatively modest reductions in testosterone 264 
observed in community-dwelling older men. The results of our study are particularly surprising, given 265 
that an increased risk of T2DM was apparent at circulating testosterone concentrations considered 266 
physiologically normal, but below the reference group of 20nmol/L, independent of age, obesity and other 267 
potential confounding factors. However, our results do not imply endorsement of testosterone 268 
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pharmacotherapy to restore circulating testosterone levels above 20nmol/L in otherwise healthy men. 269 
Studies investigating a potential beneficial impact of androgen therapy on metabolic outcomes in men 270 
with testosterone concentrations in the low or low-normal range have shown at best conflicting results. A 271 
recent double-blind placebo-controlled trial of testosterone treatment in 788 older men showed no impact 272 
on serum glucose or HbA1C 37; another study showed no change in insulin sensitivity after 36 months of 273 
treatment in 308 community-dwelling men 38. The 2018 Endocrine Society Clinical Practice Guideline on 274 
testosterone therapy in men with hypogonadism no longer recommend screening men with T2DM for low 275 
serum testosterone, and advise against using testosterone therapy to improve glycaemic control 39.  276 
Low circulating SHBG has been consistently identified as a surrogate marker for T2DM in both 277 
sexes in a number of smaller studies and meta-analyses 10,40,41, and our study supports these observations. 278 
In a meta-analysis of 13 population-based studies with 1,912 incident cases of T2DM, low SHBG was 279 
associated with increased risk of T2DM in women, irrespective of menopausal status 40. SHBG levels are 280 
typically higher in women, and our data confirm that reduced circulating concentrations are associated 281 
with a higher risk of T2DM than that observed in men. SHBG is a critical mediator of the association 282 
between sex steroids and metabolic dysfunction. The majority of circulating testosterone is bound to 283 
SHBG, such that only the unbound or ‘free’ fraction is capable of exerting effects in target tissues 42. 284 
Therefore, reduced SHBG levels in women are a surrogate marker of increased circulating active 285 
androgens. Insulin is a potent regulator of hepatic SHBG output, which is suppressed in the context of 286 
hyperinsulinemia, leading to reduced SHBG, and therefore increased free androgens, in insulin resistant 287 
states such as PCOS in women 43. It is unlikely, however, that SHBG independently plays a causal role in 288 
the pathophysiology of metabolic diseases such as T2DM. Low SHBG and testosterone levels in men are 289 
likely to be mediated by obesity in a population already at increased risk 44. We found that FAI in men did 290 
not have a negative linear association with T2DM risk, indicating that low SHBG rather than testosterone 291 
is the predominantly associated with metabolic risk in men. This supports the observations of Bhasin 45, 292 
but conflicts with those of Haring et al, who found that declining testosterone rather than SHBG levels 293 
were the main driver of metabolic syndrome in a large German cohort 46. It is important to note that FAI 294 
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must be interpreted with caution in both men and women, and is particularly inaccurate in women when 295 
the SHBG concentration falls below 30nmol/l 47.  296 
This study has a number of important limitations, not least its retrospective nature. Detailed 297 
clinical phenotyping in studies of this type are not possible. There are also no detailed data available on 298 
laboratory assays used to measure serum testosterone. This is not of particular concern in men, as 299 
physiologically higher testosterone concentrations do not represent a challenge for quantification by either 300 
radioimmunoassay (RIA) or tandem mass spectrometry techniques. In women, however, where low 301 
circulating concentrations pose significant analytical and quantification difficulties for standard RIAs, the 302 
consensus is that today measurements should be performed by liquid chromatography-tandem mass 303 
spectrometry to improve quantification and avoid cross reactivity 48. Furthermore, we have no information 304 
on the time of day blood sampling for serum testosterone took place; in men, Endocrine Society 305 
guidelines emphasize that morning samples are crucial to accurately diagnose hypogonadism 49. Lastly, 306 
we must assume that testosterone data were obtained from men and women with a clinical indication for 307 
serum measurement; this introduces a potential bias by indication. However, we believe that these 308 
limitations are ameliorated by the large patient numbers and the clear and potent gradient towards sex-309 
specific T2DM risk in the study population.  310 
In conclusion, in the largest retrospective longitudinal study of its kind, we have demonstrated 311 
evidence of a sexually dimorphic role for androgens in mediating the risk of T2DM. Reduced SHBG 312 
levels in both sexes, but particularly in women, significantly increase the risk of T2DM. These data 313 
further define androgens as a novel metabolic risk factor in men and women, but potential mechanisms 314 
underpinning these observations remain to be clarified. We suggest that women with androgen excess and 315 
men with androgen deficiency should be systematically screened for T2DM. Future studies will be 316 
required to show if reducing androgens in women, and increasing androgens in men, will improve overall 317 
metabolic health and risk of progression to overt T2DM.  318 
 319 
 320 
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Table 1: Baseline characteristics of the testosterone and SHBG cohorts stratified by sex  
Characteristics 
Men                                                                     Women                    
Serum testosterone Serum SHBG Serum testosterone Serum SHBG 
Population                            
n (%) 70,541 (46.28) 15,907 (27.45) 81,889 (53.72) 42,034 (72.55) 
Age (years)                    
mean (SD) 51.6 (14.8) 51.7 (16.0) 33.2 (10.9) 32.1 (10.6) 
Townsend index n (%)    
1 (least deprived) 20,017 (28.38) 3,997 (25.13) 18,470 (22.55) 8,753 (20.82) 
2 15,481 (21.95) 3,427 (21.54) 15,688 (19.16) 7,688 (18.29) 
3 13,687 (19.40) 3,033 (19.07) 17,043 (20.81) 8,681 (20.65) 
4 10,997 (15.59) 2,565 (16.12) 15,295 (18.68) 8,155 (19.40) 
5 (most deprived) 7,374 (10.45) 2,186 (13.74) 10,269 (12.54) 5,955 (14.17) 
Missing or implausible data 2,985 (4.23) 699 (4.39) 5,124 (6.26) 2,802 (6.67) 
BMI (kg/m2) categorised  
n (%)     
<25 19,195 (27.21) 3,995 (25.11) 32,519 (39.71) 15,975 (38.00) 
25-30 25,962 (36.80) 5,817 (36.57) 16,849 (20.58) 8,445 (20.09) 
>30 14,502 (20.56) 3,978 (25.01) 19,791 (24.17) 10,825 (25.75) 
Missing or implausible data 10,882 (15.43) 2,117 (13.31) 12,730 (15.55) 6,789 (16.15) 
Smoking status  
n (%)     
Non-smokers 53,311 (75.57) 12,264 (77.10) 61,288 (74.84) 31,557 (75.07) 
Smokers 15,325 (21.72) 3,377 (21.23) 18,020 (22.01) 9,312 (22.15) 
Missing or implausible data 1,905 (2.70) 266 (1.67) 2,581 (3.15) 1,165 (2.77) 
Confounding conditions      
PCOS   5,136 (6.27) 3,303 (7.86) 
Anovulation   21,148 (25.83) 11,288 (26.85) 
Hirsutism   9,133 (11.15) 5,064 (12.05) 
Follow-up in years  
median (IQR) 3.3 (1.5 – 6.1) 2.8 (1.3 – 4.9) 3.2 (1.3 – 6.2) 2.8 (1.2 – 5.4) 
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Table 2. Risk of incident T2DM according to the category of serum testosterone and SHBG at baseline 
 
  
IRR (95% CI); p-value 
Adjusted1 Adjusted2 Adjusted3 Adjusted4 
MEN 
Serum testosterone concentration categories (nmol/L) 
< 7 3.82 (3.31-4.41); p<0.001 
2.60 (2.25-3.00); 
p<0.001 
2.71 (2.34-3.14); 
p<0.001 
 
7 - 9.99 3.70 (3.24-4.22); p<0.001 
2.46 (2.15-2.81); 
p<0.001 
2.57 (2.24-2.94); 
p<0.001 
 
10 - 14.99 2.40 (2.13-2.71); p<0.001 
1.83 (1.62-2.06); 
p<0.001 
1.90 (1.68-2.15); 
p<0.001 
 
15 - 19.99 1.45 (1.27-1.66); p<0.001 
1.25 (1.09-1.43); 
p=0.001 
1.29 (1.13-1.47); 
p<0.001 
 
> 20 Ref Ref Ref  
Serum SHBG concentration categories (nmol/L) 
<20 8.23 (5.37-12.63); p<0.001 
5.00 (3.24-7.71); 
p<0.001 
5.74 (3.72-8.87); 
p<0.001 
 
20 - 29.99 4.30 (2.83-6.53); p<0.001 
2.92 (1.91-4.44); 
p<0.001 
3.20 (2.09-4.87); 
p<0.001 
 
30 - 39.99 3.33 (2.19-5.08); p<0.001 
2.45 (1.60-3.74); 
p<0.001 
2.61 (1.71-3.99); 
p<0.001 
 
40 - 49.99 1.56 (0.98-2.50); p=0.063 
1.28 (0.80-2.06); 
p=0.298 
1.36 (0.85-2.17); 
p=0.207 
 
50 - 59.99 1.07 (0.61-1.87); p=0.825 
0.88 (0.50-1.54); 
p=0.654 
0.91 (0.52-1.60); 
p=0.748 
 
≥60 Ref Ref Ref  
WOMEN 
Serum testosterone concentration categories (nmol/L) 
< 1 Ref Ref Ref Ref 
1.0 - 1.49 1.21 (1.02-1.43); p=0.030 
1.12 (0.95-1.33); 
p=0.184 
1.12 (0.94-1.32); 
p=0.204 
1.11 (0.94-1.32); 
p=0.213 
1.5 - 1.99 1.45 (1.23-1.70); p<0.001 
1.26 (1.07-1.48); 
p=0.005 
1.23 (1.05-1.45); 
p=0.011 
1.23 (1.04-1.44); 
p=0.013 
2.0 - 2.49 1.70 (1.42-2.04); p<0.001 
1.34 (1.12-1.61); 
p=0.002 
1.30 (1.08-1.56); 
p=0.005 
1.28 (1.07-1.54); 
p=0.008 
2.5 - 2.99 2.07 (1.67-2.58); p<0.001 
1.59 (1.27-1.97); 
p<0.001 
1.53 (1.23-1.90); 
p<0.001 
1.50 (1.20-1.87); 
p<0.001 
3.0 - 3.49 2.51 (1.90-3.32); p<0.001 
1.74 (1.31-2.30); 
p<0.001 
1.68 (1.27-2.23); 
p<0.001 
1.62 (1.22-2.15); 
p=0.001 
≥ 3.5 3.00 (2.36-3.82); p<0.001 
2.09 (1.64-2.67); 
p<0.001 
1.98 (1.55-2.52); 
p<0.001 
1.89 (1.48-2.42); 
P<0.001 
Serum SHBG concentration categories (nmol/L) 
<20 19.76 (14.36-27.21); p<0.001 
8.96 (6.42-12.50); 
p<0.001 
9.23 (6.61-12.88); 
p<0.001 
9.13 (6.53-12.75); 
p<0.001 
20 - 29.99 8.66 (6.29-11.93); p<0.001 
4.45 (3.20-6.19); 
p<0.001 
4.48 (3.22-6.24); 
p<0.001 
4.44 (3.19-6.18); 
p<0.001 
30 - 39.99 4.66 (3.31-6.57); p<0.001 
2.69 (1.90-3.82); 
p<0.001 
2.70 (1.91-3.84); 
p<0.001 
2.69 (1.90-3.82); 
p<0.001 
40 - 49.99 2.99 (2.04-4.38); p<0.001 
2.05 (1.40-3.02); 
p<0.001 
2.08 (1.41-3.05); 
p<0.001 
2.07 (1.41-3.05); 
p<0.001 
50 - 59.99 1.64 (1.02-2.64); p=0.043 
1.29 (0.80-2.08); 
p=0.295 
1.29 (0.80-2.07); 
p=0.304 
1.29 (0.80-2.08); 
p=0.301 
≥60 Ref Ref Ref Ref 
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1 Adjusted for age,  
2 Adjusted for age, BMI,  
3 Adjusted for age, BMI, Townsend index, smoking status 
4 Adjusted for age, BMI, Townsend index, smoking status, PCOS 
 
Abbreviations: IRR, incidence rate ratio; SHBG, sex hormone-binding globulin; T2DM, type 2 diabetes mellitus 
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FIGURE LEGENDS 
Figure 1: Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone-binding globulin 
(SHBG) concentration categories in men. (A) Adjusted Incidence Rate Ratios (aIRRs) for diabetes in 70,541 men with 
serum testosterone measurements. (B) Distribution of 70,541 men across each quintile of serum testosterone 
concentration. (C) aIRRs for serum SHBG concentrations for incident diabetes in 15,907 men. (D) Distribution of 15,907 
men across each category of serum SHBG concentration.  
 
Figure 2: Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone-binding globulin 
(SHBG) concentrations in women. (A) Adjusted Incidence Rate Ratios (aIRRs) for incident diabetes in 81,889 women 
with serum testosterone measurements. (B) Distribution of 81,889 women across each category of serum testosterone 
concentration. (C) aIRRs for serum SHBG concentrations for incident diabetes in 42,034 women with serum SHBG 
measurements. (D) Distribution of 42,034 women across each category of serum SHBG concentration.  
 
